Brazil health regulator Anvisa on Wednesday allowed resumption of late-stage Brazilian clinical trials for China's Sinovac COVID-19 vaccine, which had been suspended due to a study subject's death that was registered in Sao Paulo as a suicide.

Brazilian medical institute Butantan said in a statement it would restart trials later on Wednesday.

Brazil's president, Jair Bolsonaro, a longtime China critic who has baselessly dismissed the Sinovac vaccine as lacking in credibility, had hailed Monday's suspension as a personal victory.